The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004 Dec 15;104(13):3858-64
Date
08/26/2004Pubmed ID
15328151DOI
10.1182/blood-2004-06-2223Scopus ID
2-s2.0-10244270631 (requires institutional sign-in at Scopus site) 252 CitationsAbstract
Recombinant factor VIIa was initially developed for the treatment of hemorrhagic episodes in hemophilic patients with inhibitors to factors VIII and IX. After its introduction, it has also been used "off-label" to enhance hemostasis in nonhemophilic patients who experience bleeding episodes not responsive to conventional therapy. Evidence so far indicates that the use of factor VIIa in hemophilic patients with inhibitors is both safe and effective. Anecdotal reports also suggest that the product is safe and effective in controlling bleeding in nonhemophilic patients. However, its use in these conditions has not been approved by the FDA, and conclusive evidence of its effectiveness from controlled clinical trials is not yet available. Several questions pertaining to the use of factor VIIa require further investigation, including the mechanism of action; the optimal dose; definitive indications; ultimate safety; and laboratory tests for monitoring therapy.
Author List
Roberts HR, Monroe DM, White GCAuthor
Gilbert C. White MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Blood Coagulation DisordersFactor VIIa
Hemophilia A
Hemophilia B
Hemorrhage
Humans
Recombinant Proteins
Safety
